Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 271

1.

5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype.

Applebaum MA, Barr EK, Karpus J, Nie J, Zhang Z, Armstrong AE, Uppal S, Sukhanova M, Zhang W, Chlenski A, Salwen HR, Wilkinson E, Dobratic M, Grossman R, Godley LA, Stranger BE, He C, Cohn SL.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00402. Epub 2019 May 16.

2.

Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study.

Braunstein SE, London WB, Kreissman SG, Villablanca JG, Davidoff AM, DeSantes K, Castleberry RP, Murray K, Diller L, Matthay K, Cohn SL, Shulkin B, von Allmen D, Parisi MT, Van Ryn C, Park JR, La Quaglia MP, Haas-Kogan DA.

Pediatr Blood Cancer. 2019 Jul;66(7):e27736. doi: 10.1002/pbc.27736. Epub 2019 Apr 9.

PMID:
30968542
3.

Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.

Chlenski A, Park C, Dobratic M, Salwen HR, Budke B, Park JH, Miller R, Applebaum MA, Wilkinson E, Nakamura Y, Connell PP, Cohn SL.

Mol Cancer Ther. 2019 Mar;18(3):507-516. doi: 10.1158/1535-7163.MCT-18-0819. Epub 2019 Jan 23.

PMID:
30674566
4.

Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System.

Naranjo A, Irwin MS, Hogarty MD, Cohn SL, Park JR, London WB.

JCO Clin Cancer Inform. 2018 Dec;2:1-15. doi: 10.1200/CCI.17.00140.

5.

The challenge of defining "ultra-high-risk" neuroblastoma.

Morgenstern DA, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Moreno L, Park JR, Pearson AD, Schleiermacher G, Valteau-Couanet D, London WB, Irwin MS.

Pediatr Blood Cancer. 2019 Apr;66(4):e27556. doi: 10.1002/pbc.27556. Epub 2018 Nov 26. Review.

PMID:
30479064
6.

Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.

Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM.

J Clin Oncol. 2019 Jan 10;37(2):115-124. doi: 10.1200/JCO.18.00419. Epub 2018 Nov 16.

PMID:
30444686
7.

Perioperative cardiovascular medicine: 5 questions for 2018.

Modha K, Johnson KM, Kuperman E, Grant PJ, Slawski B, Pfeifer K, Cohn SL.

Cleve Clin J Med. 2018 Nov;85(11):853-859. doi: 10.3949/ccjm.85a.18066. Review.

8.

Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma.

Sokol EA, Engelmann R, Kang W, Pinto N, Starkey A, Lai H, Nadel H, Shulkin BL, Pu Y, Appelbaum D, Yanik GA, Cohn SL, Armato SG 3rd, Volchenboum S.

Pediatr Blood Cancer. 2018 Dec;65(12):e27417. doi: 10.1002/pbc.27417. Epub 2018 Sep 10.

PMID:
30198643
9.

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.

DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith K, Granger MM, Weiss B, Park JR, Macy ME, Cohn SL, Yanik G, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A.

Clin Cancer Res. 2018 Dec 15;24(24):6142-6149. doi: 10.1158/1078-0432.CCR-18-1381. Epub 2018 Aug 9.

PMID:
30093449
10.

Clinical pearls in perioperative medicine.

Cohn SL, Litin SC, Bundrick JB.

Dis Mon. 2018 Aug;64(8):385-392. doi: 10.1016/j.disamonth.2018.05.006. Epub 2018 Jun 5. Review. No abstract available.

PMID:
29880267
11.

In reply: Perioperative interruption of dual antiplatelet therapy.

Munyon R, Cohn SL, Slawski B, Smetana GW, Pfeifer K.

Cleve Clin J Med. 2018 Apr;85(4):262. doi: 10.3949/ccjm.85c.04002. No abstract available.

12.

MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group.

Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A, Van Ryn C, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Ikegaki N, Shimada H.

Oncotarget. 2017 Dec 15;9(5):6416-6432. doi: 10.18632/oncotarget.23740. eCollection 2018 Jan 19.

13.

Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

de Alarcon PA, Matthay KK, London WB, Naranjo A, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL.

Lancet Child Adolesc Health. 2018 Jan;2(1):25-34. doi: 10.1016/S2352-4642(17)30130-X. Epub 2017 Nov 3.

14.

Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy.

Nassin ML, Nicolaou E, Gurbuxani S, Cohn SL, Cunningham JM, LaBelle JL.

Biol Blood Marrow Transplant. 2018 Mar;24(3):452-459. doi: 10.1016/j.bbmt.2017.11.012. Epub 2017 Dec 5.

15.

2017 Update in perioperative medicine: 6 questions answered.

Munyon R, Cohn SL, Slawski B, Smetana GW, Pfeifer K.

Cleve Clin J Med. 2017 Nov;84(11):863-872. doi: 10.3949/ccjm.84a.17068. Review.

16.

Comparison of 4 Cardiac Risk Calculators in Predicting Postoperative Cardiac Complications After Noncardiac Operations.

Cohn SL, Fernandez Ros N.

Am J Cardiol. 2018 Jan 1;121(1):125-130. doi: 10.1016/j.amjcard.2017.09.031. Epub 2017 Oct 13.

PMID:
29126584
17.

Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma.

Hungate EA, Applebaum MA, Skol AD, Vaksman Z, Diamond M, McDaniel L, Volchenboum SL, Stranger BE, Maris JM, Diskin SJ, Onel K, Cohn SL.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx093.

18.

Emerging and investigational therapies for neuroblastoma.

Applebaum MA, Desai AV, Glade Bender JL, Cohn SL.

Expert Opin Orphan Drugs. 2017;5(4):355-368. doi: 10.1080/21678707.2017.1304212. Epub 2017 Mar 17.

19.

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM.

Clin Cancer Res. 2018 Jan 1;24(1):189-196. doi: 10.1158/1078-0432.CCR-17-1767. Epub 2017 Oct 2.

20.

Composite tumor with pheochromocytoma and immature neuroblastoma: report of two cases with cytogenetic analysis and discussion of current terminology.

Tran L, Fitzpatrick C, Cohn SL, Pytel P.

Virchows Arch. 2017 Oct;471(4):553-557. doi: 10.1007/s00428-017-2225-9. Epub 2017 Sep 1. No abstract available.

21.

Data Commons to Support Pediatric Cancer Research.

Volchenboum SL, Cox SM, Heath A, Resnick A, Cohn SL, Grossman R.

Am Soc Clin Oncol Educ Book. 2017;37:746-752. doi: 10.14694/EDBK_175029. Review.

22.

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.

Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D.

J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4. Review.

23.

The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.

Secola R, Marachelian A, Cohn SL, Toy B, Neville K, Granger M, Brentlinger A, Martin G.

J Pediatr Oncol Nurs. 2017 May/Jun;34(3):160-172. doi: 10.1177/1043454216680595. Epub 2017 Jan 6.

PMID:
28061552
24.

Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.

Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, Pinto N, Volchenboum SL, Park JR, Naranjo A, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ.

Eur J Cancer. 2017 Feb;72:177-185. doi: 10.1016/j.ejca.2016.11.022. Epub 2016 Dec 26.

25.

Preoperative Evaluation for Noncardiac Surgery.

Cohn SL.

Ann Intern Med. 2016 Dec 6;165(11):ITC81-ITC96. doi: 10.7326/AITC201612060. Review.

PMID:
27919097
26.

Preoperative Evaluation for Noncardiac Surgery (Japanese Version).

Cohn SL.

Ann Intern Med. 2016 Dec 6;165(11):JITC81-JITC96. doi: 10.7326/IsTranslatedFrom_AITC201612060_Japanese. No abstract available.

PMID:
30140906
27.

Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.

Chen L, Humphreys A, Turnbull L, Bellini A, Schleiermacher G, Salwen H, Cohn SL, Bown N, Tweddle DA.

Oncotarget. 2016 Dec 27;7(52):87301-87311. doi: 10.18632/oncotarget.13541.

28.

Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids.

Chlenski A, Dobratic M, Salwen HR, Applebaum M, Guerrero LJ, Miller R, DeWane G, Solomaha E, Marks JD, Cohn SL.

Oncotarget. 2016 Nov 22;7(47):77696-77706. doi: 10.18632/oncotarget.12773.

29.

Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients.

Applebaum MA, Jha AR, Kao C, Hernandez KM, DeWane G, Salwen HR, Chlenski A, Dobratic M, Mariani CJ, Godley LA, Prabhakar N, White K, Stranger BE, Cohn SL.

Oncotarget. 2016 Nov 22;7(47):76816-76826. doi: 10.18632/oncotarget.12713.

30.

Update in perioperative cardiac medicine.

Cohn SL, Dutta S, Slawski BA, Grant PJ, Smetana GW.

Cleve Clin J Med. 2016 Oct;83(10):723-730. doi: 10.3949/ccjm.83a.16076. Review.

31.

Rebound thymic hyperplasia following high dose chemotherapy and stem cell transplant in three neuroblastoma patients.

Sokol E, Huang E, Pytel P, Cohn SL, Pinto N.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26226. Epub 2016 Sep 24. No abstract available.

PMID:
27663277
32.

Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database.

Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS.

Eur J Cancer. 2016 Sep;65:1-10. doi: 10.1016/j.ejca.2016.06.005. Epub 2016 Jul 17.

PMID:
27434878
33.

Patient/Family Education for Newly Diagnosed Pediatric Oncology Patients.

Landier W, Ahern J, Barakat LP, Bhatia S, Bingen KM, Bondurant PG, Cohn SL, Dobrozsi SK, Haugen M, Herring RA, Hooke MC, Martin M, Murphy K, Newman AR, Rodgers CC, Ruccione KS, Sullivan J, Weiss M, Withycombe J, Yasui L, Hockenberry M.

J Pediatr Oncol Nurs. 2016 Nov/Dec;33(6):422-431. doi: 10.1177/1043454216655983. Epub 2016 Jul 9.

34.

The cardiac consult for patients undergoing non-cardiac surgery.

Cohn SL.

Heart. 2016 Aug 15;102(16):1322-32. doi: 10.1136/heartjnl-2015-307997. Epub 2016 Jun 20. Review. No abstract available.

PMID:
27325586
35.

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.

Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP.

Pediatr Blood Cancer. 2016 Aug;63(8):1349-56. doi: 10.1002/pbc.25994. Epub 2016 Apr 19.

PMID:
27092812
36.

Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.

Pinto N, Mayfield JR, Raca G, Applebaum MA, Chlenski A, Sukhanova M, Bagatell R, Irwin MS, Little A, Rawwas J, Gosiengfiao Y, Delattre O, Janoueix-Lerosey I, Lapouble E, Schleiermacher G, Cohn SL.

Pediatr Blood Cancer. 2016 Jun;63(6):1019-23. doi: 10.1002/pbc.25934. Epub 2016 Feb 10.

37.

Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.

Marachelian A, Desai A, Balis F, Katzenstein H, Qayed M, Armstrong M, Neville KA, Cohn SL, Bush M, Gunawan R, Lim AP, Smith MA, Smith LM.

Cancer Chemother Pharmacol. 2016 Feb;77(2):405-12. doi: 10.1007/s00280-015-2955-9. Epub 2016 Jan 20.

38.

Genetic discoveries and treatment advances in neuroblastoma.

Bagatell R, Cohn SL.

Curr Opin Pediatr. 2016 Feb;28(1):19-25. doi: 10.1097/MOP.0000000000000296. Review.

39.

Updates in perioperative medicine.

Dutta S, Cohn SL, Pfeifer KJ, Slawski BA, Smetana GW, Jaffer AK.

J Hosp Med. 2016 Mar;11(3):231-6. doi: 10.1002/jhm.2487. Epub 2015 Sep 18. Review.

PMID:
26381728
40.

Postoperative troponin surveillance: A diagnostic dilemma.

Cohn SL.

Cleve Clin J Med. 2015 Sep;82(9):603-5. doi: 10.3949/ccjm.82a.15113. No abstract available.

41.

Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL.

J Clin Oncol. 2015 Sep 20;33(27):3008-17. doi: 10.1200/JCO.2014.59.4648. Epub 2015 Aug 24. Review.

42.

A Selfless Act.

Cohn SL.

J Clin Oncol. 2015 Nov 10;33(32):3834-5. doi: 10.1200/JCO.2015.62.5137. Epub 2015 Aug 10. No abstract available.

PMID:
26261250
43.

Surveillance of Childhood Cancer Survivors: A Lifelong Affair.

Applebaum MA, Cohn SL.

J Clin Oncol. 2015 Nov 1;33(31):3531-2. doi: 10.1200/JCO.2015.62.7703. Epub 2015 Aug 10. No abstract available.

PMID:
26261248
44.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.

45.

Stem Cell Transplant-Associated Wernicke Encephalopathy in a Patient with High-Risk Neuroblastoma.

Darlington WS, Pinto N, Hecktman HM, Cohn SL, LaBelle JL.

Pediatr Blood Cancer. 2015 Dec;62(12):2232-4. doi: 10.1002/pbc.25650. Epub 2015 Jul 14.

PMID:
26174546
46.

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.

Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Shimada H.

Br J Cancer. 2015 Jun 30;113(1):57-63. doi: 10.1038/bjc.2015.188. Epub 2015 Jun 2.

47.

Barriers to the use of paediatric clinical practice guidelines in rural and regional New South Wales Australia.

Cohn SL, Gautam B, Preddy JS, Connors JR, Kennedy SE.

Aust J Rural Health. 2016 Feb;24(1):23-8. doi: 10.1111/ajr.12190. Epub 2015 May 6.

PMID:
25945922
48.

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.

DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK.

Clin Cancer Res. 2015 Jun 15;21(12):2715-21. doi: 10.1158/1078-0432.CCR-14-3240. Epub 2015 Feb 18.

49.

Perioperative cardiovascular medicine: an update of the literature 2013-2014.

Slawski BA, Cohn SL, Pfeifer KJ, Dutta S, Jaffer AK, Smetana GW.

Hosp Pract (1995). 2014 Oct;42(4):126-34. doi: 10.3810/hp.2014.10.1149. Review.

PMID:
25502136
50.

Perioperative anticoagulation and renal disease: an update.

Dutta S, Jaffer AK, Slawski BA, Pfeifer KJ, Smetana GW, Cohn SL.

Hosp Pract (1995). 2014 Dec;42(5):132-8. doi: 10.3810/hp.2014.12.1166. Review.

PMID:
25485925

Supplemental Content

Support Center